| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Filing example | Nana-val relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL), other EBV-positive cancers | NDA | — | Nanomedicine | Oncology | ||
NDA Filing example | Nana-val relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL), other EBV-positive cancers | NDA | — | Nanomedicine | Oncology | ||
NDA Filing example | Nana-val relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL), other EBV-positive cancers | NDA | — | Nanomedicine | Oncology |
Recent Updates
Recently added Catalysts
Viracta Therapeutics, Inc.$0.01
0 (-8.6%)
D 29Pipeline Score Richly Valued Biotech · Clinical
Market Cap
6.56 M
EPS
-1.10
P/E Ratio
-
Value Trade
4.26 K
SEC Financials
Q3 2024Dilution Risk
R&D Expenses
7.18 M
Total Assets
21.96 M
Total Liabilities
28.57 M
Equity
-6.62 M
D/E Ratio
12,345
-8.84 %
Week
-17.5 %
1 Month
-25 %
3 Month
-64.89 %
6 Month
-99.04 %
5 Year
-100 %
All Time
Cash Data
Cash Position
21.13 M
Monthly Burn
3.40 M
Runway
0 mo
Burn Trend
StableSEC Filing
Nov 13, 2024
Overview
Volume
484.03 K
52 Week Range
0.01 - 1.31
% held by Insiders
0.03 %
% held by Institutions
0.31 %
Enterprise Value
-3.54 M
Total Shares
39.74 M
Short %
0.01 %
Float Shares
28.69 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D29
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal5
Drugs Scored0.2x
rNPV / MCap Top 33%
Micro Cap (rank 607 of 905)
Percentile RankViracta Therapeutics, Inc. faces pipeline headwinds (29/100), with $1.5B risk-adjusted pipeline value, led by Vosaroxin in Leukemia (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vosaroxin Small molecule | Acute Myeloid Leukemia | Phase 3 | NCT03338348 | 46% | $783M | COMPLETED | 720 | - | - | Oct 31, 2019 | - | Oct 28, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VIRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Viracta Therapeutics, Inc. (VIRX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
VIRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VIRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VIRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VIRX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
VIRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How VIRX ranks across every disease it competes inCompetitive Position is a premium feature
See how VIRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial